APOE rs405509: Promoter Variant, Longevity, and Brain Aging
rs405509 is a well-studied single nucleotide polymorphism located in the promoter region of the apolipoprotein E (APOE) gene, often designated in scientific literature as -219T/G. By altering transcription factor binding sites, this variation modulates how much APOE protein is produced in the brain and vascular system. Scientific studies associate alleles at this site with differences in cognitive healthspan, exceptional longevity, and modified risk patterns when co-inherited with classic APOE alleles.
What each genotype means
Higher promoter transcriptional activity
Carrying two copies of the G allele is associated with relatively higher baseline transcription of the APOE gene compared to the T allele. In population research, this genotype has been linked to higher plasma ApoE levels and may exert a modest protective or moderating effect against cognitive decline and Alzheimer's disease pathology, particularly when co-occurring with APOE-epsilon-4. However, research findings remain mixed across different cohorts and ancestries.
Carried by approximately 20% to 25% of European Americans and roughly 5% to 10% of East Asians, while being substantially more prevalent in individuals of African ancestry.
Intermediate promoter transcriptional activity
Carrying one G allele and one T allele confers an intermediate level of APOE promoter activity and expression. Epidemiological studies suggest an intermediate risk profile for age-related cognitive changes, often moderating the impact of other APOE isoforms in an allele-dose-dependent manner. Evidence evaluating rs405509 remains limited and is heavily influenced by genomic background and linkage disequilibrium.
Carried by approximately 45% to 50% of individuals in European and East Asian populations.
Reduced promoter transcriptional activity
Carrying two copies of the T allele is associated with lower APOE promoter activity, reduced APOE transcription, and lower circulating ApoE levels. While some centenarian studies note complex haplotypic links with longevity, multiple clinical cohorts have observed that this genotype synergizes with the APOE-epsilon-4 allele to increase vulnerability to cognitive decline and lower the age of Alzheimer's onset. The strength of this modifying effect is modest overall and varies significantly by ancestral background.
Carried by roughly 25% to 30% of European Americans, more than 50% of East Asians, and under 10% of African Americans.
Genetic Architecture and Biological Function
The rs405509 single nucleotide polymorphism is located on chromosome 19 within the 5-prime upstream promoter region of the APOE gene. In biochemical research, it is frequently described as the -219T/G promoter polymorphism. Because of its location in a regulatory sequence rather than a protein-coding exon, rs405509 does not alter the amino acid sequence of apolipoprotein E. Instead, functional laboratory assays demonstrate that it directly alters transcriptional regulatory activity. Electrophoretic mobility shift assays have confirmed that the T and G alleles exhibit differential binding affinity for nuclear transcription factors in both neuronal and hepatoma cells. In vitro experiments show that the presence of the G allele significantly increases APOE promoter transcription compared to the T allele, whereas the TT genotype has been shown in human brain tissue analyses to correlate with decreased baseline levels of APOE expression.
The Role of the APOE Gene
The APOE gene provides instructions for producing apolipoprotein E, an essential protein involved in lipid homeostasis, cholesterol transport, and tissue repair throughout the body. While APOE is synthesized in abundance by the liver to regulate circulating plasma lipoproteins, it is also heavily produced by astrocytes and microglia in the central nervous system. In the brain, apolipoprotein E facilitates the distribution of essential lipids required for synaptic maintenance, neuronal repair, and the clearance of amyloid-beta peptides. The gene is best known for its common coding variants, rs429358 and rs7412, which define the classic epsilon-2, epsilon-3, and epsilon-4 isoforms. Variations that govern how efficiently the gene is transcribed, such as rs405509, provide a critical second layer of regulation by determining the overall abundance of these functional proteins.
Research on Longevity, Cognition, and Alzheimer's Risk
Scientific investigation into rs405509 spans several decades, revealing nuanced and sometimes complex associations across different human populations. In centenarian studies, specific promoter haplotypes carrying rs405509 have been investigated for associations with exceptional human longevity and well-preserved cognitive faculties in nonagenarians. Concurrently, neuroimaging and neuropsychological studies report that non-demented older individuals with the TT genotype may exhibit subtle changes in fronto-parietal functional connectivity and cognitive processing speed. Furthermore, large multiracial studies have demonstrated that rs405509 acts as an important effect modifier for individuals carrying the classic APOE epsilon-4 risk allele. In those carrying epsilon-4, having additional T alleles at rs405509 has been associated with an amplified risk of late-onset Alzheimer's disease and earlier age of onset, while the G allele appears to exert a moderating influence.
Evidence Strength and Clinical Limitations
Current scientific evidence for rs405509 is categorized as limited to moderate, primarily because the magnitude of its observable effect varies according to genetic background and linkage disequilibrium with other APOE alleles. While biochemical data clearly confirm that the polymorphism changes transcriptional activity, epidemiological associations with dementia and longevity have not always yielded identical results across global cohorts. Some observational studies in European cohorts found modest or neutral standalone associations with dementia incidence once classic APOE isoforms were controlled for, whereas cohorts of East Asian ancestry have shown more pronounced modifier effects. Because rs405509 is a modifier rather than a causative mutation, clinical guidelines from diagnostic bodies do not consider it a standalone diagnostic test for neurodegenerative or cardiovascular diseases.
Translating Genetic Findings into Personal Health
Learning your rs405509 genotype provides educational perspective on your unique regulatory genetics, but it cannot determine whether you will live to exceptional age or develop cognitive decline. Complex outcomes like longevity and neurodegenerative vulnerability arise from the interplay of hundreds of genetic variants, cardiovascular parameters, nutrition, sleep quality, and physical activity. Individuals interested in supporting long-term brain health and longevity benefit most from evidence-based foundational habits, such as regular aerobic exercise, lifelong cognitive engagement, and maintaining healthy blood pressure and lipid levels. Genomic findings should never replace formal medical evaluation. If you have questions about personal health risks or family history of dementia, discussing your profile with a certified genetic counselor or physician is the recommended approach.
How common is this variant?
The minor allele frequency for rs405509 is approximately 0.45 across European populations and roughly 0.49 in East Asian populations, meaning both the G and T alleles are broadly and almost evenly distributed worldwide.
Frequently asked questions
What is the difference between rs405509 and classic APOE epsilon status?
Classic APOE status (epsilon-2, epsilon-3, and epsilon-4) is determined by two coding SNPs, rs429358 and rs7412, which change the amino acid structure of the protein. By contrast, rs405509 is located in the gene's promoter region and influences how much APOE protein is produced, acting as a potential volume dial rather than changing protein shape.
Does having the rs405509 TT genotype mean I will develop Alzheimer's disease?
No, having the TT genotype is not a diagnosis and does not cause Alzheimer's disease. While researchers have observed statistical correlations with brain functional changes and increased risk in individuals who also carry APOE epsilon-4, many individuals with the TT genotype live long, cognitively intact lives.
Why is rs405509 researched in relation to longevity?
Because apolipoprotein E plays a foundational role in cellular repair, lipid transport, and brain health, variations that fine-tune its expression have been investigated in centenarians. Specific combinations of APOE promoter and coding alleles appear more frequently among long-lived individuals who maintain good cognitive health.
Can lifestyle choices influence the effects of this APOE promoter variant?
Yes. Modifiable lifestyle factors—including cardiovascular exercise, an anti-inflammatory diet, adequate sleep, and managing blood pressure and cholesterol—have strong, proven effects on cognitive healthspan that can mitigate genetic vulnerabilities across the APOE region.
Sources & further reading
Educational information only, last refreshed 9/11/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs405509?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in APOE
Variant in the APOE/TOMM40 locus associated with late-onset Alzheimer's disease risk.
Downstream variant in the APOE region associated with lipid metabolism profiles and healthspan indicators.
Variant (c.497G>A, p.Arg166Gln) in the APOE gene known as Apolipoprotein E4 Christchurch, which has been shown in clinical case studies to confer resistance to familial Alzheimer's disease pathology.
Upstream regulatory variant influencing APOE transcription and plasma lipid modulation.
Defines the APOE ε2 allele, associated with lower LDL cholesterol and reduced risk of Alzheimer's disease.
Regulatory variant in the APOE promoter region modulating transcriptional activity and risk for late-onset neurodegeneration.